Bronchiolitis in a patient with talcosis

K Reijula, P Pääkkö, R Kerttula, O Taikina-Aho, T Tuuponen, J Hassi

Despite environmental monitoring, widely used occupational standards, and an increasing knowledge of the causative agents of occupational respiratory diseases, new cases of pneumoconiosis still occur. Pulmonary disorders caused by inhalation of talc (magnesium silicate, Mg₃Si₄O₁₀(OH)₂) have been described among workers in various industries.¹²

Interstitial inflammation with lymphocytic infiltration, granulomas, and birefringent material are typical findings in lung tissue of patients with talcosis.¹² Bronchiolar changes, however, have never been described and this paper is the first report of bronchiolitis in patients with talcosis.

Case report
A 43 year old talc mine loader who operated a tractor was admitted to a local chest hospital with dyspnoea, cough, and phlegm. He had worked as a talc loader since 1960. The patient used paper masks only occasionally to prevent dust inhalation. Mineralogical examination had established that talc from the talc mine occurs in plate and granular forms but not in fibrous form. Personal dust samples were collected inside the tractor during talc loading in 1976 and 1986. The total dust concentration was 86 mg/m³ in 1976 after which time dust filters were installed into the artificial ventilation system of the tractors. In 1986 the total dust concentration was 3-5 mg/m³.

The patient had smoked 20 cigarettes a day for 21 years. Contact dermatitis due to nickel was found in patch tests in 1976. He had no history of allergic rhinoconjunctivitis, atopic dermatitis, or other significant diseases.

He had had dyspnoea, cough, and production of phlegm for eight months. Cough and phlegm occurred both in the mornings and during the work shift. He had dyspnoea only when heavy dust was present and a few hours after exposure to talc dust. The symptoms diminished during weekends. He was admitted to Päivärinne chest hospital where tests of lung function showed a restrictive ventilatory defect and decreased diffusing capacity (table). No abnormalities were detected on chest x ray film or in routine laboratory tests. No bronchial hyperreactivity was found by metacholine bronchodilator (salbutamol).

Precipitating antibodies to Aspergillus fumigatus, A umbrosus, Thermoactinomyces vulgaris, and Faenia rectivirgula (Micropolyspora faeni) could not be detected in the patient’s serum by immunodiffusion tests. Cultures for M tuberculosis, other bacteria, and fungi were negative and eosinophilic granulocytes were not present in sputum. All tests to measure antibodies to viral agents were negative. Antinuclear antibodies or rheumatoid factor were not found. Skin prick tests with nine inhalant allergens were negative for immediate weal and flare reactions.

The patient was treated with a bronchodilator (salbutamol) for three months after which he was reexamined. He complained of shortness of breath and wheezing after inhaling dust at work, during exercise, and when breathing cold air. A slight improvement was found in diffusing capacity values. Other lung functions were unchanged. No remarkable changes had occurred in laboratory tests or on chest x ray film. Theophylline treatment was added to the patient’s regimen.

During a third examination an improvement of (FEV₁) (30%) was noted after treatment with salbutamol. The daily range of peak flow values was 500–600 l/minute. The patient was treated with prednisolone for one week without an improvement in symptoms or lung function.

After six months without medication he presented with increased dyspnoea, cough, and wheezing, which had occurred during dust inhalation at work. Lung function tests were unchanged. Blood eosinophil (509 × 10⁹/l) and total serum IgE concentrations (159 IU/ml) were slightly increased. With bronchodilator treatment an improvement of FEV₁ (20%) was found. During treatment with salbutamol in hospital the mean peak flow values also improved.
Clinical data for patient with talcosis

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung function:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FVC (l)</td>
<td>3.89 (75)*</td>
<td>3.77 (72)</td>
<td>3.43 (66)</td>
<td>3.73 (70)</td>
<td>4.29 (85)</td>
</tr>
<tr>
<td>FEV1 (l)</td>
<td>3.10 (75)</td>
<td>2.74 (65)</td>
<td>2.88 (67)</td>
<td>3.21 (79)</td>
<td>3.32 (85)</td>
</tr>
<tr>
<td>FEV1%</td>
<td>84</td>
<td>81</td>
<td>84</td>
<td>86</td>
<td>77</td>
</tr>
<tr>
<td>DLCO (l)</td>
<td>23.4 (75)</td>
<td>24.3 (78)</td>
<td>24.4 (79)</td>
<td>26.5 (80)</td>
<td>24.2 (77)</td>
</tr>
<tr>
<td>TLC (l)</td>
<td>5.05</td>
<td>4.70</td>
<td>4.30</td>
<td>6.68</td>
<td>5.50</td>
</tr>
<tr>
<td>Laboratory tests:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESR (mm h)</td>
<td>7</td>
<td>7</td>
<td>9</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>B-leuc ($\times 10^9$ l)</td>
<td>9.7</td>
<td>8.3</td>
<td>11.0</td>
<td>10.0</td>
<td>8.0</td>
</tr>
<tr>
<td>B-eos ($\times 10^9$ l)</td>
<td>300</td>
<td>269</td>
<td>509</td>
<td>253</td>
<td>231</td>
</tr>
</tbody>
</table>

*Numbers in parentheses are percentages of predicted values.
FVC = forced vital capacity; FEV1 = forced expiratory volume in one second; FEV1% = FEV1/FVC $\times$ 100; DLCO = diffusing capacity for carbon monoxide; RV = residual volume; TLC = total lung capacity; ESR = erythrocyte sedimentation rate; B-leuc = blood leucocyte concentration; B-eos = blood eosinophil concentration.

Five months later he presented with increasing dyspnoea, cough, and fever. Chest x-ray film showed diffuse, soft densities in the middle and lower lung zones. Further changes in lung function or in laboratory tests were not found. A transbronchial biopsy was performed and showed granulomatous infiltration with macrophages including birefringent material. An open lung biopsy was conducted in May 1984 to elucidate the definite etiology of the granulomatous lung infiltration. Biopsy specimens were treated as described earlier. The samples containing dust were examined using a JEOL 100 STEM fitted with a PGT 1000 energy dispersive spectrometer at 100 kV.

Light microscopy showed a fairly normal alveolar pattern. Most of the non-respiratory and respiratory bronchioles had lymphocytic infiltration of the mucosa (fig 1). A few interstitial epithelioid cell granulomas were seen. Slight fibrosis was found in the interstitium, with hypertrophy of arterial media. Interstitial tissue contained black dust, especially around muscular arterioles, bronchioles, and in subpleural areas; several birefringent crystals or sticks were seen in polarised light. Multinucleated giant cells were also present. Some of these contained either a few dust particles or asteroid bodies. The histological picture suggested talcosis.

Interstitial macrophages that contained one or two particles a cell were detected by electron microscopy (fig 2a). These particles showed a spectrum typical of talc in energy dispersive x-ray analysis (fig 2b). No silica or asbestos was detected in the lungs.

After the lung biopsy the patient continued treatment with a bronchodilator. He returned to work two months later and irregularly used a helmet type ventilatory device. Eight months later he presented with less severe dyspnoea, cough, and phlegm without fever. No remarkable changes were found in lung function tests. His oxygen saturation and electrocardiogram were normal both at rest and during exercise. Peak flow values varied from 520 to 600 l per minute. Bronchial hyperreactivity by metacholine provocation test could not be detected. The patient retired in February 1986.

Figure 1  Light micrograph of open lung biopsy showing a bronchiole with mucosal infiltration of mononuclear inflammatory cells, mainly lymphocytes and plasma cells (H and E $\times$ 100).
the first clinical examination. Thus exposure to talc dust was most evident before the clinical examinations.

As in previous studies, dyspnoea and cough were the first symptoms. It is difficult to estimate the onset of the respiratory symptoms caused by talc dust because of the patient’s heavy smoking, which undoubtedly explains some of the symptoms suggesting chronic bronchitis. The patient noticed, however, an increase in the symptoms, which he related to inhalation of talc dust, and which appeared eight months before the first examination. As previously described, a restrictive ventilatory defect with reduced vital capacity was detected. Also, a slight decrease in diffusing capacity and an obstructive ventilatory defect were found, together with lymphocytic infiltration of the mucosa of non-respiratory and respiratory bronchioles. Bronchiolitis has not been shown previously in talcosis. The obstructive ventilatory defect may be partly explained by bronchiolitis in this case.

Recent studies have shown that non-asbestos mineral dust can cause small airway lesions accompanied by air flow obstruction. These lesions, with deposits of fibres and pigmentation, have been detected in the walls of non-respiratory and respiratory bronchioles and alveolar ducts. In this “mineral dust airway disease” inflammatory cell infiltration has not been detected in the walls of bronchioltes. Also, injury to the bronchiolar wall was assumed to be a non-specific reaction of small airways to inorganic particulates. Further studies are needed to prove whether the bronchiolitis found in this patient represents a general phenomenon in workers exposed to talc dust.

We thank Eeva Liedes MD, Jordan Fink MD, and Victor Ferrans MD for their interest in the present study. The work has been supported by grants from the Finnish Antituberculosis Association, the Finnish Work Environment Fund, the Paulo Foundation, and the Foundation for the Study of Allergy, Helsinki, Finland.

Requests for reprints to: Kari Reijula MD, Oulu Regional Institute of Occupational Health, PO Box 451, SF-90101 Oulu, Finland.


Accepted 6 August 1990
Bronchiolitis in a patient with talcosis.

K Reijula, P Pääkkö, R Kerttula, O Taikina-Aho, T Tuuponen and J Hassi

doi: 10.1136/oem.48.2.140

Updated information and services can be found at:
http://oem.bmj.com/content/48/2/140.citation

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/